Healio
Healio
MDD collection banner

Major Depressive Disorder Video Perspectives

Healio spoke with an expert psychiatrist to answer important questions in the major depressive disorder space.
Choose a Section
  • Michael Thase, MD

    • Michael Thase, MD

    In this video series, Michael Thase, MD, professor of psychiatry and director of the mood and anxiety section at Penn Medicine, talked about:

    • exciting developments in major depressive disorder treatment, including:
      • FDA-approved options: esketamine (Spravato, Janssen), brexanolone (Zulresso, Sage Therapeutics) and Auvelity (dextromethorphan-bupropion, Axome Therapeutics); and
      • therapies showing potential: zuranolone (SAGE-217/BIIB125; Biogen, Sage Therapeutics), esmethadone (REL-1017, Relmada Therapetuics) and psilocybin;
    • approaching treatment-resistant depression;
    • his view on the relationship between stigma and depression;
    • access to care and other important areas of unmet need in MDD; and
    • the role of mental health apps to help "improve and facilitate care."

    Read more about

    major depressive disorder
    treatment-resistant depression
    health services accessibility
    mental health service
    ketamine
    psilocybin
    perelman school of medicine university of pennsylvania
    You've successfully added to your alerts. You will receive an email when new content is published.

    Click Here to Manage Email Alerts

    We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.